Newsletter

Menu

Three pharma stocks to buy and hold this quarter

By Toby |

Healthcare and pharma companies hold a lot of promise in the present landscape, where most countries have high aging demographics. Though some pharma stocks tend to be volatile, with a lot depending on new entrants, biosimilars and regulatory approvals, we have identified three companies that you could consider including in your portfolio in the fourth quarter.

Regeneron Pharmaceuticals (REGN): Though much of Regeneron’s growth between 2012 and 2015 was attributable to its blockbuster retinal treatment Eylea, the company is now gradually expanding research into other promising areas including heart and immune system disorders.

Only last month, it received an FDA approval for its skin cancer treatment called Libtayo. Notably, this is the first treatment to receive approval for advanced cutaneous squamous cell carcinoma, a kind of skin cancer that causes around 7,000 fatalities in the US every year.

There are a few other potential FDA approvals waiting in the pipeline, the most recent one expected later this month, for the expanded use of Dupixent antibody to patients suffering from Asthma. An approval could make Dupixent Regeneron’s second blockbuster drug.

These are ably backed by the S&P 500 component’s Praluent, a cholesterol-control drug that had witnessed a sleeper success.

Eylea lifts Regeneron Q2 earnings

Rhythm Pharmaceuticals (RYTM): A relative newcomer, Rhythm is a bioparma firm that focuses on rare and fatal genetic disorders. Its investigational drug setmelanotide, which will be used to treat Alstrom Syndrome and Bardet-Biedl Syndrome, had recently reported positive results from the phase 2 study.

The Boston-headquartered company’s stock, which started trading on Nasdaq in October last year, is flattish at the moment. However, the stock has an average price target of $38.20, which is at a 52% upside to the current trading price of $25.19.

The third stage trial is set to initiate this quarter and a success would give a gargantuan push to the stock.

RYTM stock has an average price target of $38.20, which is at a 52% upside to the current trading price of $25.19.

AbbVie (ABBV): Abbvie has had a rough ride this year, spurred by FDA Commissioner Scott Gottlieb’s intention to make entry of biosimilars to markets less cumbersome. The move, if materialized, would greatly dent the sale of its flagship rheumatoid arthritis treatment Humira.

However, this has created a great buying opportunity for a stock that has enormous potential. It’s true that investors need to keep a watch on the regulatory developments in the biosimilar front. But such an action need not entirely break the stock.  AbbVie already has licensing tie-ups in place with rivals Amgen (AMGN) and Mylan (MYL) to delay any potential biosimilar launches until the next three to four years. The company would continue to do this.

The company also has other successful products such as Mavyret and Imbruvica, even if Humira takes a hit.

Pharmacy growth might aid Walgreens to deliver upbeat Q4 results

DISCLAIMER: The article does not necessarily imply the views of AlphaStreet, and contains opinions of the author alone. 

Advertisement

More on this Company

ipo news

Alumis looks to raise $300 million in IPO. Here’s what you need to know

June 25, 2024

Ocean Biomedical co-founder Jack Elias to receive US patent for pulmonary fibrosis treatments

April 20, 2023

Abbott Laboratories (ABT) Q1 2022 Infographic: Key financials and quarterly highlights

April 20, 2022

98 responses to “Three pharma stocks to buy and hold this quarter”

  3. apps for pc download

    […]Wonderful story, reckoned we could combine several unrelated data, nonetheless actually worth taking a appear, whoa did a single study about Mid East has got additional problerms too […]

  6. Colt Python For Sale

    […]although web sites we backlink to below are considerably not associated to ours, we really feel they may be in fact really worth a go through, so possess a look[…]

  9. male pocket stroker

    […]Wonderful story, reckoned we could combine a number of unrelated information, nonetheless truly really worth taking a appear, whoa did one understand about Mid East has got a lot more problerms at the same time […]

  12. 5.56 green tips

    […]although websites we backlink to beneath are considerably not related to ours, we feel they are in fact worth a go by means of, so have a look[…]

  25. penis extension

    […]check beneath, are some totally unrelated internet sites to ours, however, they are most trustworthy sources that we use[…]

  27. Rob Black

    […]although internet sites we backlink to below are considerably not related to ours, we feel they’re really worth a go by way of, so possess a look[…]

  42. Moroccan hash

    […]although internet websites we backlink to below are considerably not connected to ours, we really feel they’re actually really worth a go via, so have a look[…]

  48. …Awesome website

    […] What web host are you the usage of? Can I get affiliate hyperlink to your host? I wish web site loaded up as quickly as yours lol[…]

  50. …Take a look for more Information on that topic

    […] What web host are you the usage of? Can I get affiliate hyperlink to your host? I wish web site loaded up as quickly as yours lol[…]

  66. Find more there:

    […] What host are you using? Can I am getting your associate link on your host? I want site loaded up as fast as yours lol[…]

  72. …Click here for or more Information

    […] What host are you the use of? Can I am getting your associate link on your host? I desire my website loaded up as fast as yours lol[…]

  90. …Links

    […] What web host are you using? Can I get affiliate hyperlink in your host? I want site loaded up as quickly as yours lol[…]

  96. …Websites you should visit

    […]I am now not sure where you are getting your info, however good topic.[…]

  97. Look here for more:

    […]Wow, fantastic weblog structure! How lengthy have you ever been running a blog for?[…]

Top